<DOC>
	<DOCNO>NCT03079505</DOCNO>
	<brief_summary>DANIN study randomize , phase 3 clinical trial compare 'head head ' Nilotinib versus Dasatinib upfront therapy patient chronic myeloid leukemia . The efficacy drug test measure BCR/ABL ( BCR-ABL = fusion gene BCR ( breakpoint cluster region gene/BCR gene product ) ABL ( Abelson proto-oncogene ) ) use European Leukemia net recommendation study conduct NCCCR ( National Center Cancer Care &amp; Research ) sample size calculation detail statistic part clinical hematologist recruit patient include consent process inclusion exclusion criterion molecular pathologist molecular test clinical research coordinator fellows CRF ( Case Report Form ) well quality life questionnaire apply protocol evaluation cardiac evaluation Molecular monitoring BCR-ABL1 transcript assess treatment response CML ( Chronic Myeloid Leukemia ) .</brief_summary>
	<brief_title>Dasatinib Versus Nilotinib Treatment Na√Øve Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Male female patient 18 year . 2 . Patients must follow : enrol within 3 month initial diagnosis CMLCP ( Chronic Phase ) ( date initial diagnosis date first cytogenetic analysis ) cytogenetic confirmation Philadelphia chromosome variant ( 9 ; 22 ) translocation patient may secondary chromosomal abnormality addition Philadelphia chromosome . &lt; 15 % blast peripheral blood bone marrow ; &lt; 30 % blast plus promyelocytes peripheral blood bone marrow ; &lt; 20 % basophils peripheral blood , 100 x 109/L platelet great evidence extramedullary leukaemic involvement , exception hepatosplenomegaly . 3 . Written voluntary inform consent . 1 Patients Phnegative , BCRABLpositive , disease NOT eligible study . 2 . Any prior treatment CML : tyrosine kinase inhibitor ( eg imatinib , dasatinib ) ; busulphan ; interferonalpha ; homoharringtonine ; cytosine arabinoside ; investigational agent ( hydroxycarbamide anagrelide drug permit ) . Patients ineligible study receive prior therapy interferonalpha imatinib . No exception . 3 . Patients receive prior chemotherapy , include regimen use peripheral blood progenitor cell ( PBPCs ) mobilisation haematopoietic progenitorcell transplantation . ( It allowable collect unmobilised PBPCs diagnosis . ) 4 . Patient form prior haemopoietic stem cell transplant , either autograft allograft . 5 . Patients ECOG ( Eastern Cooperative Oncology Group ) Performance Status Score 2 less . 6 . Patients serum bilirubin , AST ( aspartate aminotransferase ) , ALT ( alanine aminotransferase ) , creatinine concentration &gt; 2.0 x institutional upper limit normal range ( IULN ) . 7 . Patients International normalized ratio ( INR ) partial thromboplastin time ( PTT ) &gt; 1.5 x IULN , exception patient treatment oral anticoagulant . 8 . Patients uncontrolled medical disease diabetes mellitus , thyroid dysfunction , neuropsychiatric disorder , infection , angina , Grade 3/4 cardiac problem define New York Heart Association Criteria . 9 . Patients know positivity human immunodeficiency virus ( HIV ) ; baseline test HIV require . 10 . Patients undergone major surgery within 4 week Study Day 1 , recover prior major surgery . 11 . Patients : pregnant , breast feeding , childbearing potential without negative pregnancy test prior Study Day 1 , male female childbearing potential unwilling use barrier contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . 12 . Patients history another malignancy either currently within past five year , exception basal cell skin carcinoma cervical carcinoma situ . 13 . Patients history noncompliance medical regimen consider potentially unreliable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>